LURAP1L and breast carcinoma: The data in (Fig. 4B) showed a significant positive correlation between LURAP1L-AS1 and ESR1 expression in breast cancer patients (r = 0.169, p = 1.58 × 10−8), underscoring LURAP1L-AS1 as a clinically relevant marker in ER+ breast cancer.